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People with diabetes experience morbidity and mortality from unregulated microvascular remodeling,
which may be linked to hyperglycemia. Elevated glucose leads to extracellular matrix collagen glycation,
which delays endothelial capillary-like tube formation in vitro. Glucose also increases endothelial cell
ﬁbroblast growth factor-2 (FGF-2) release and extracellular matrix storage, which should increase tube
formation. In this study, we determined if FGF-2 could restore plasminogen system activity and angio-
genic function in endothelial cells on glycated collagen. Human umbilical vein endothelial cells cultured
on native or glycated collagen substrates were stimulated with FGF-2. Plasminogen system activity, cell
migration, and capillary-like tube formation were measured, along with plasminogen system protein and
mRNA levels. Glycated collagen decreased endothelial cell plasminogen system activity, cell migration,
and tube length. FGF-2 did not restore plasminogen system activity or tube formation in cells on glycated
collagen, despite decreasing plasminogen activator inhibitor-1 (PAI-1) protein level. We now show that
PAI-1 binds to glycated collagen, which may localize PAI-1 to the extracellular matrix. These data suggest
that FGF-2 may not restore angiogenic functions in endothelial cells on glycated collagen due to PAI-1
bound to glycated collagen.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetic hyperglycemia is implicated in diseases of increased
angiogenesis (e.g. diabetic nephropathy and retinopathy) as well as
diseases of decreased angiogenesis (e.g., diabetic neuropathy and
impaired wound healing) [1–4]. In angiogenesis, endothelial cells
must degrade the extracellular matrix so that they can migrate and
invade into the surrounding tissue, where they form capillary tubes
[5]. Glucose modiﬁes the extracellular matrix in ways that could
both increase and decrease angiogenesis. Glucose reacts with amino
protein groups to glycate collagen via the Maillard reaction, which
enhances collagen cross-linking, makes it more resistant to pro-
teolysis, and inhibits angiogenesis [6–10]. We previously showed
that extracellular matrix from endothelial cells cultured in high
glucose contains more ﬁbroblast growth factor-2 (FGF-2), and ret-
inal tissue from diabetic patients with proliferative retinopathy
showed increased FGF-2 [11,12]. FGF-2 promotes angiogenesis in
part by increasing extracellular matrix proteolysis [13].
Extracellular matrix proteolysis in angiogenesis is driven by the
plasminogen system and matrix metalloproteinases [14]. In theB.V. This is an open access article u
. Mathew),plasminogen system, urokinase plasminogen activator (uPA) is the
primary activator of pericellular matrix proteolysis [15]. Cells se-
crete uPA as a single chain pro-enzyme (scuPA) [16]. Secreted
scuPA binds to its cell surface receptor (uPAR), where plasmin
cleaves it to the active two-chain uPA form. uPA then cleaves
plasminogen to plasmin, which either directly breaks down matrix
components or activates matrix metalloproteinases [17]. Plasmi-
nogen activator inhibitor-1 (PAI-1) is the primary uPA inhibitor
[18]. Cells secrete PAI-1 in active form but it rapidly decays into its
latent form unless it binds to multimeric vitronectin in plasma,
platelets, or extracellular matrix [19]. Active PAI-1 binds to and
inactivates receptor bound uPA, preventing proteolysis [20]. The
uPA:PAI-1 balance is postulated to break down enough of the
extracellular matrix to enable cell invasion yet still maintain ade-
quate matrix stability so that cells can adhere to and migrate along
the matrix.
Both glycated collagen and FGF-2 impact the plasminogen sys-
tem, albeit in opposite directions. Chen et al. showed delayed ca-
pillary cord branching in human umbilical vein endothelial cells on
glycated as compared to native collagen gels, which was ascribed to
elevated PAI-1 [10]. Elevated PAI-1 is prevalent in patients with
metabolic syndrome, and both diabetic animals and humans
showed increased PAI-1 in the arterial wall [21–23]. Thus glycated
collagen shifts the plasminogen system balance in the anti-angio-
genic direction by increasing PAI-1. FGF-2 increases uPA and PAI-1nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FGF-2 stimulates more uPA than PAI-1. Thus FGF-2 moves the
plasminogen system in a pro-angiogenic direction.
In this study, we investigated whether FGF-2 could restore
angiogenic functions in endothelial cells on glycated collagen by
activating the plasminogen system. Endothelial cells were cultured
on native or glycated collagen with or without FGF-2. Plasminogen
activity, cell 3D migration, and capillary-like tube formation were
measured along with uPA, PAI-1, and uPAR. We now show that
FGF-2 did not restore angiogenic functions in cells on glycated
collagen despite decreasing PAI-1, perhaps due to increased PAI-1
binding to glycated collagen.2. Materials and methods
2.1. Cell culture and collagen glycation
Human umbilical vein endothelial cells (HUVEC, passages 4–9;
Lonza) were maintained in low glucose (5.5 mM) Endothelium
Growth Medium (EGM-2; Lonza) supplemented with 5% fetal bo-
vine serum (FBS; Hyclone), 1% penicillin–streptomycin (Gibco), and
1% glutamine (Gibco). HUVEC were selected because they are
widely used for in vitro endothelial cell studies, show a robust FGF-2
response, and react with human plasminogen system proteins and0.0
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Fig. 1. Glycated collagen decreased endothelial cell uPA activity, 3D migration, and tu
(A) uPA activity was measured using Chromozym PL. HUVEC seeded on native and glycate
(B) 3D cell migration was measured using a Boyden chamber. HUVEC 7 50 ng/ml FGF-2
After 24 h, cells that migrated to the chamber bottom were labeled with Hoechst, image
to native collagen without FGF-2. (C) For tube formation, HUVEC were added to native a
imaged by phase contrast microscopy and tube length was analyzed. (D) Sample tube for
vs. native collagen. Each experiment was completed in triplicate and repeated three timantibodies. In addition, HUVEC were used in the original paper in
which glycated collagen delayed endothelial cell capillary-like cord
branching [10]. Collagen was glycated by incubating 100 mg/mL
collagen type I (BD Biosciences) with 500 mM D-glucose-6-phos-
phate (G6P; Sigma) in phosphate buffered saline (PBS) at 37 °C for
4 weeks. Collagen glycation was validated via autoﬂuorescence and
decreased collagenase digestion as described previously [26]. Mul-
timeric vitronectin was created by incubating 1 mg/ml native vi-
tronectin (Molecular Innovations) with 6 M urea (Sigma) in 1
tris-buffered saline (TBS) for 1 h at 37 °C. After dialysis in 1 TBS
for 18 h, multimeric vitronectin was collected and stored at 80 °C
until use. Cell culture substrates were coated with 50 mg/ml native
or glycated collagen (BD Biosciences) overnight at 4 °C. After
washing, 25,000 cells/cm2 were seeded on these substrates in En-
dothelial Basal Medium (EBM-2; Lonza) supplemented with 5% FBS
and allowed to attach for 48 h EBM-2, which is EGM-2 without
growth factors and cytokines, was used for all experiments to en-
able measurement of FGF-2 effects.
2.2. uPA activity
Chromozym PL was used to determine uPA activity in cell ex-
tracts. In our assay, uPA cleaved exogenous plasminogen to plasmin,
which then cleaved Chromozyme PL into a residual peptide and
4-nitroaniline (405 nm). HUVEC were cultured for 48 h on nativeNative Collagen Glycated Collagen
+FGF-2
**
* *
ø
ø
50ng/ml FGF-2
be length compared to native collagen. FGF-2 only partially abrogated this effect.
d collagen coated substrates for 48 h were stimulated with 50 ng/ml FGF-2 for 24 h.
were added to a Transwell insert coated with 100 mg/ml native or glycated collagen.
d by ﬂuorescent microscopy, and quantiﬁed with ImageJ. Samples were normalized
nd glycated collagen gels (4 mg/ml) 7 FGF-2 (50 ng/ml). After 18 h, samples were
mation images, with tubes indicated by black arrows. npo0.01; nnpo0.01 glycated
es.
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2 (PeproTech) was added to cells in fresh EBM-2 for 24 h. HUVEC
were lysed in T/T buffer (60 mM Tris hydrochloride, 0.5% Triton
X-100) for 5 min, after which cell extracts were centrifuged at
10,000 g for 10 min to remove insoluble material. A ﬁnal solution of
cell extract, 127 ng/mL Chromozym PL (Roche), and 67 mU/mL plas-
minogen (Roche) was mixed in a 96 well plate. Absorbance (405 nm)
was measured for 24 h in an Inﬁnite 200 PRO microplate reader
(TECAN) maintained at 37 °C. The change in 4-nitroaniline absor-
bance at 405 nm is directly proportional to uPA enzymatic activity.
Absorbance was plotted vs. time, and the linear region slope (ΔA/
min) was used to calculate uPA activity via the following equation:
y V v duPA Activit U/ml / A/min .( ) = [( ·є· )·(Δ )]
where V is total volume (300 ml), v is cell extract volume (33 ml), є
is absorbance coefﬁcient for 4-nitroaniline (1.4104 mol1 cm1),
and d is light path (1 cm).3. 3D migration
HUVEC 3D migration was assessed using a Boyden chamber
assay. The bottom of a Transwell chamber (6.5 mm diameter, 8 mm
pore size; Corning Costar) was coated with 100 mg/ml native or
glycated collagen, which was allowed to gel for 1 h at room tem-
perature. 150,000 cells were then added to the top of each
chamber in EBM-2 with 5% FBS with and without FGF-2 (50 ng/
ml). EBM-2 with 10% FBS was added to the bottom chamber.
Samples were incubated for 24 h at 37 °C, after which cells re-
maining in the upper Transwell chamber were removed byFig. 2. Glycated collagen increased PAI-1 protein level, and FGF-2 treatment returned
glycated collagen coated substrates for 48 h were stimulated with 50 ng/ml FGF-2 for 2
Western blot. (B, C, D) Band intensity for PAI-1, uPA, and uPAR, respectively, was quanti
each. npo0.01; nnpo0.01 glycated vs. native collagen. Each experiment was completedswabbing. Cells that migrated to the chamber bottomwere labeled
with Hoechst (10 ng/ml; Invitrogen) for 30 min. 5 randomly se-
lected areas per sample were imaged using an Olympus IX81 in-
verted ﬂuorescent microscope. Cell number was quantiﬁed with
ImageJ.
3.1. Tube formation
HUVEC tube formation was assessed on native or glycated
collagen gels. Native collagen gels were prepared by incubating
50 ml 4 mg/ml collagen I at 37 °C for 1 h. Glycated collagen gels
were prepared by incubating native collagen gels with 500 mM
G6P for 4 weeks at 37 °C. 15,000 HUVEC were added to each gel in
EBM-2 with 5% FBS with and without FGF-2 (50 ng/ml). Cells were
incubated for 18 h at 37 °C, after which samples were imaged
using a Nikon Eclipse TS100 phase contrast microscope (5 images
per well). Tube length was manually analyzed using ImageJ by an
objective technician with no knowledge of the coded images [27].
3.2. uPA, PAI-1, and uPAR protein and mRNA levels
uPA, PAI-1, and uPAR protein and mRNA levels were quantiﬁed
by Western blot and real-time quantitative reverse transcriptase
polymerase chain reaction (qRT-PCR), respectively. HUVEC were
cultured for 48 h on native or glycated collagen coated substrates
as described, after which they were treated with 50 ng/ml FGF-2
for 2–24 h. For Western blot, cells were scraped off the surface in
ice-cold lysis buffer (20 mM Tris, 150 mM NaCl, 1% Triton X-100,
0.1% SDS, 2 mM EDTA, 2 mM NaVO4, 2 mM PMSF, 50 mM NaF, 10%PAI-1 back to the native collagen level at 24 h. (A) HUVEC seeded on native and
4 h. Cell extracts were collected and normalized protein samples were analyzed by
ﬁed and normalized to GAPDH. 1 representative Western blot of 3, with 3 samples
in triplicate and repeated three times.
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normalized for protein content, separated by SDS-PAGE on a 4–
12% Bis-Tris gel (Invitrogen), and transferred to nitrocellulose
membranes using the Invitrogen i-Blot system. Membranes were
incubated overnight at 4 °C with primary antibodies to uPA, PAI-1,
or uPAR (Santa Cruz), followed by a secondary horseradish per-
oxidase-conjugated antibody (Promega) for 2 h at room tem-
perature. Protein bands were detected using an enhanced chemi-
luminescence kit (Western Lightning, PerkinElmer) and visualized
with a Fluorchem digital imager (Alpha Innotech). Band intensity
was quantiﬁed using AlphaEase FC software.
For RT-PCR, RNA was isolated using an RNeasy Mini Kit (Qiagen)
according to the manufacturer protocol. RNA concentration was
quantiﬁed by measuring sample absorbance (260 nm) using a Na-
noDrop 1000 (Thermo Scientiﬁc), and RNA purity (1.8–1.99 for all
samples) was determined using the 260/280 nm ratio. RNA samples
were stored at 80 °C until use. Primers for uPA (forward: 5′-
AATGACTGTTGTGAAGCTGATTTC-3′; reverse: 5′-AGGGGTCCCCCT-
GAGTCT-3′), PAI-1 (forward: 5′-TCCAGCAGCTGAATTCCTG-3′; re-
verse: 5′-GCTGGAGACATCTGCATCCT-3′), and GAPDH (forward: 5′-
ACCACAGTCCATGCCATCAC-3′; reverse: 5′-TCCACCACCCTGTTGCTG-
TA-3′) were from Integrated DNA Technologies. GAPDH was se-
lected as the housekeeping gene because its mRNA levels do not
change in HUVEC treated with FGF-2 [28]. PCR was performed on a
LightCycler 480 Real-Time PCR System using LightCycler 480 RNA-
Master Hydrolysis probes (Roche) according to the manufacturer
protocol. Each 20 μl reaction contained 150 ng total RNA, 0.4 μM
Universal Probe #66 (Roche), 0.5 μM uPA or PAI-1 primer, 3.25 mM
Mn(OAc)2, 1 Master Hydrolysis Probes and 1 Enhancer (Roche).Native Collagen Glycated Collagen
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Fig. 3. Glycated collagen did not alter uPA or PAI-1 mRNA, whereas FGF-2 treatment decr
glycated collagen coated substrates for 48 h were stimulated with 50 ng/ml FGF-2 for (A,
and (B, D) PAI-1 mRNA levels were normalized to GAPDH for each condition. #po0.05, n
times.Thermal cycling conditions were set as follows: 1 cycle reverse
transcription at 63 °C for 20 min; 1 cycle denaturation at 95 °C for
30 s; and 45 cycles ampliﬁcation (as per manufacturer instructions)
and annealing at 95 °C for 10 s with a second ampliﬁcation at 60 °C
for 45 s with single acquisition mode. The protocol was selected to
allow primers to anneal at a greater efﬁciency. In all cases, the Ct
values were between 17 and 25. mRNA level was quantiﬁed using
both the standard curve and the second derivative maximum
method. All standard curves and samples were determined to have
a maximum error of 0.05 and doubling rate greater than 1.85. All
reactions were performed in triplicate. Reactions without the
template DNA (no template controls, NTC) and without cell sample
were the negative controls.
3.3. PAI-1 binding to extracellular matrix proteins
PAI-1 binding to native collagen, glycated collagen and vi-
tronectin was assessed using a solid phase binding assay [29]. 96
well plates were coated with the appropriate extracellular matrix
protein as described and blocked using PBS with 3% BSA and 0.05%
Tween. 1 mg/ml PAI-1 (in tris-buffered saline with 1% BSA, 0.01%
Tween, and 1 mM CaCl2) was added to each well and incubated for
2 h at 37 °C. After thorough washing, bound PAI-1 was detected by
incubating samples with a PAI-1 primary antibody (Santa Cruz)
followed by a horse radish peroxidase-conjugated secondary an-
tibody (Promega). The assay was developed using a two-step
process to decrease background absorbance. First, 1.8 nM 2,2-azi-
nobis(3-ethylbenzthiazidine-6-sulfonic) acid (Sigma) in 0.1 M so-
dium citrate, pH 4.5 was added to samples for 30 min at 37 °C. ThisNative Collagen Glycated Collagen
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eased PAI-1 mRNA on both native and glycated collagen. HUVEC seeded on native and
B) 2 or (C, D) 24 h. One-step RT-PCR was performed using a LightCycler 480. (A, C) uPA
po0.01, nnpo 0.01. Each experiment was completed in triplicate and repeated three
J.G. Mathew, A.M. Clyne / Biochemistry and Biophysics Reports 4 (2015) 104–110108was then replaced with 1.8 mM 2,2-azinobis(3-ethylbenzthiazi-
dine-6-sulfonic) acid and incubated for 30 min at 37 °C. Absor-
bance (405 nm) was quantiﬁed using a microplate reader.
3.4. Statistical analysis
Statistical analysis was performed with GraphPad Prism and
Instat software. Samples were collected in triplicate and experi-
ments performed at least two times. Data are graphed as
mean7standard deviation. Signiﬁcance between two groups was
compared using Student's t-test. Comparisons among multiple
groups were analyzed by two-way ANOVA with a Bonferroni post-
hoc test. p-values are indicated in the ﬁgures by #po0.05,
*po0.01, **po0.001, unless otherwise indicated.4. Results and discussion
4.1. Endothelial cell response to FGF-2 on native and glycated
collagen
Glycated collagen was previously shown to delay endothelial
cell capillary cord branching, perhaps due to elevated PAI-1 [10].
We therefore measured whether FGF-2 could reverse glycated
collagen-induced changes in plasminogen activity and angiogenic
functions. HUVEC attachment and spreading were statistically si-
milar on both native and glycated collagen coated substrates (data
not shown). However, uPA activity was 35% lower in cells on gly-
cated compared to native collagen (Fig. 1A). While FGF-2 increased
uPA activity by 51% in cells on native collagen, it only increased
uPA activity by 22% in cells on glycated collagen. Cell proliferation
(assessed by cell counts) and 2D migration (assessed by cageNative Collagen Glyc
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Fig. 4. PAI-1 bound to glycated collagen more than to native collagen, and exogenous PA
coated with native collagen, glycated collagen, or multimeric vitronectin were incubate
npo0.01 compared to native collagen. (B) 15,000 HUVEC were added to native or glycat
phase contrast microscopy and tube length was analyzed with ImageJ. Samples were n
compare uPA and PAI-1 effects. npo0.01 compared to samples without uPA or PAI-1 on
at least two times.assay) increased with FGF-2 on both native and glycated collagen,
with no differences based on substrate composition (data not
shown). In contrast, collagen glycation did change endothelial cell
3D migration through a collagen coated Boyden chamber. 27%
fewer cells migrated through the Boyden chamber on glycated as
compared to native collagen. FGF-2 stimulation restored cell mi-
gration on glycated collagen back to native collagen levels (Fig. 1B).
Endothelial cell tube length was 48% lower for HUVEC on glycated
collagen gels as compared to native collagen gels. FGF-2 more than
doubled tube length on native collagen gels, but only increased
tube length 46% on glycated collagen gels (Fig. 1C; sample images
in Fig. 1D). Thus FGF-2 fully rescued 3D migration but not plas-
minogen system activity or capillary-like tube formation from
glycated collagen effects.
4.2. Glycated collagen and FGF-2 effects on plasminogen system
components
Plasminogen system activity derives from uPA binding to uPAR
and the uPA:PAI-1 balance. We therefore measured uPA, uPAR, and
PAI-1 protein levels by Western blot (Fig. 2A) to determine which
proteins contributed to decreased plasminogen system activity in
cells on glycated collagen. For the selected time points (48 h on
glycated collagen followed by 2, 6, 12, or 24 h of FGF-2 stimula-
tion), glycated collagen and FGF-2 only changed PAI-1 protein le-
vels at 24 h. HUVEC on glycated collagen showed more than
double the PAI-1 protein as cells on native collagen, and FGF-2
brought the PAI-1 level down to that of cells on native collagen
(24 h data in Fig. 2B). FGF-2 had no effect on PAI-1 protein in cells
on native collagen, and neither glycated collagen nor FGF-2 af-
fected uPA or uPAR levels across all time points (24 h data in
Fig. 2C and D).ated Collagen Vitronectin
ycated Collagen
+uPA
+PAI-1
I-1 only decreased tube length in endothelial cells on glycated collagen. (A) Plates
d with 1 mg/ml PAI-1. A solid-phase binding assay was used to detect bound PAI-1.
ed collagen gels 7 12 IU/ml uPA or 1 ng/ml PAI-1. After 18 h, tubes were imaged by
ormalized to the control without uPA or PAI-1 on the respective substrate to best
the respective substrate. Each experiment was completed in triplicate and repeated
J.G. Mathew, A.M. Clyne / Biochemistry and Biophysics Reports 4 (2015) 104–110 109We next measured uPA and PAI-1 mRNA levels at the same
time points to determine if changes in PAI-1 protein levels were
related to PAI-1 production. Neither glycated collagen nor FGF-2
affected uPA mRNA at 2 h, which was consistent with Western blot
data (Fig. 3A). Glycated collagen induced a small but signiﬁcant
increase in PAI-1 mRNA at 2 h, and FGF-2 decreased this effect
(Fig. 3B). After 24 h, uPA mRNA was similar across all samples but
FGF-2 decreased PAI-1 mRNA by 30% in cells on both native and
glycated collagen (Fig. 3C and D).
4.3. PAI-1 binding to glycated collagen
We and others previously showed that matrix protein dena-
turation and glycation can induce structural changes that alter cell
and protein binding [30–33]. We therefore hypothesized that PAI-
1 levels increased in cells on glycated collagen partially due to PAI-
1 binding. Indeed, more than three times as much PAI-1 bound to
glycated collagen as compared to native collagen in an equilibrium
binding assay (Fig. 4). FGF-2 did not displace the PAI-1 bound to
glycated collagen (data not shown). We then added exogenous uPA
and PAI-1 to HUVEC cultured on native or glycated collagen gels.
Whereas uPA increased capillary-like tube length on both sub-
strates, PAI-1 only decreased tube length in cell on glycated col-
lagen gels. These data suggest that PAI-1 binding to glycated col-
lagen mediates its effect on angiogenic processes.
Glucose induced changes in the extracellular matrix, such as
collagen glycation, decrease endothelial capillary-like tube for-
mation in vitro [10]. We previously showed that glucose also in-
creases endothelial FGF-2 release and matrix storage [11]. We now
show that FGF-2 only partially restored plasminogen system ac-
tivity in cells on glycated collagen. FGF-2 decreased PAI-1 levels in
cells on glycated collagen. However, FGF-2 did not decrease PAI-1
binding to glycated collagen, which may localize PAI-1 to the ex-
tracellular matrix [30,31,34,35]. While PAI-1 binding and activity
were previously shown to increase with glycated ﬁbrin [32], we
are the ﬁrst to report that PAI-1 also binds to glycated collagen,
and that this may modulate plasminogen system activity.
While these studies describe interesting new interactions
among growth factors, glycated collagen, and the plasminogen
system, they are not without limitations. We used HUVEC to relate
our results to previous work in the literature and because they
form capillary-like tubes in vitro. However, microvascular en-
dothelial cells may be a better model for future work. In our ex-
periments, FGF-2 did not affect uPA or PAI-1 mRNA. This was in-
itially surprising, since others had previously shown that FGF-2
regulates both uPA and PAI-1 [24,25]. However, FGF-2 typically has
less effect on the plasminogen system in human as compared to
animal cells, and therefore continuous FGF-2 stimulation or
mediator proteins may be required to enhance FGF-2 effects
[14,24,36]. In fact, when we added ﬁbrinogen to our FGF-2 sti-
mulated samples, we did observe signiﬁcant increases in uPA and
PAI-1 mRNA. Finally, some of our observed effects on plasminogen
system activity could relate to tissue plasminogen activator (tPA),
rather than uPA. tPA is produced by endothelial cells, although it is
primarily thought to generate plasmin for blood ﬁbrinolysis [37].
We focused on uPA due to its importance in angiogenic functions;
however the possibility of tPA effects cannot be excluded.Acknowledgments
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